# lung adenocarcinoma (LUAD) - grok-4.6

- Benchmark system: E2seq + Agent RAG
- Repeat: 4
- Task type: PROGNOSIS
- Tissue / sample source: lung adenocarcinoma tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: xAI / grok-4.6
- Message SHA-256: a2c9355177479f23c6c81afe1b39ba697ac131cc344bb83120b98e2c6bbfee49
- Response HTTP status: 200
- Prompt tokens: 49814
- Completion tokens: 20014
- Reasoning tokens: 13560
- Total tokens: 69828
- API requests reported: 4
- Elapsed seconds: 131.121
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 957.651
- Question handoff seconds: 970.897
- Final benchmark system: E2seq; file rank 3/5; original repeat 4; model vendor: xAI

---
**Overall biological interpretation**  
The prognostic analysis of LUAD tumor tissue identifies 96 risk-associated genes (HR > 1) and 4 protective-associated genes (HR < 1) across 100 selected features, with most exhibiting extreme HR magnitudes and P = 0, FDR = 0. These features are predominantly non-coding RNAs, pseudogenes, and unannotated loci, indicating widespread dysregulation of non-coding transcripts as potential drivers of poor overall survival. A minority of protein-coding genes (e.g., DKK1, KRT6A, RGS20, FUT4) map to core oncogenic and glycosylation programs, suggesting that non-coding RNA burden may amplify Wnt signaling and glycosylation defects that promote LUAD progression and aggressive outcomes.

**Core biological programs**  
1. **Non-coding RNA and pseudogene burden** (risk-associated, HR > 1)  
Major supporting genes: RBMY1F, RP11-998D10.4, FAM9A, LINC00448, MIR509-1, TTTY4C, AF241725.6, MIR3924, and dozens of additional LINC/RP11/UNMAPPED entries.  
Most appropriate standardized pathway: RNA polymerase II transcription and non-coding RNA processing (Reactome/GO biological process annotations).  
These genes collectively indicate a program in which abundant non-coding transcripts correlate with markedly elevated mortality risk, likely through regulatory interference with mRNA stability, chromatin remodeling, or tumor-stroma crosstalk in LUAD.  
Evidence strength: direct from the input survival statistics (100/100 genes with FDR = 0). Limitations: extreme HR values raise concern for technical artifacts; no independent-cohort replication statistic supplied.

2. **Wnt signaling pathway dysregulation** (risk-associated, HR > 1)  
Major supporting genes: DKK1, TLE1, LINC01312, LINC02178, LDLRAD3, KRT6A.  
Most appropriate standardized pathway: Wnt signaling pathway (KEGG/GO:0030111, GO:2000096).  
DKK1 (canonical Wnt inhibitor) and TLE1 (transcriptional co-repressor) show modest but consistent HR elevation (>1.3), while several lncRNAs co-occur in the same annotated module, implying coordinated suppression or amplification of canonical Wnt activity that favors tumor cell survival and metastasis in LUAD.  
Evidence strength: direct HR/P/FDR from cohort + pathway ontology overlap. Limitations: only partial gene coverage; external cohort statistics absent.

3. **Glycosylation and O-glycan remodeling** (mixed, with protective and risk signals)  
Major supporting genes: FUT4, CMAHP, KRT6A.  
Most appropriate standardized pathway: Mannose-type O-glycan biosynthesis (KEGG) and glycosphingolipid biosynthesis.  
FUT4 (α1,3-fucosyltransferase) and KRT6A (keratin with glycosylation motifs) associate with risk, whereas CMAHP (CMP-N-acetylneuraminic acid hydroxylase) is protective (HR < 1), suggesting a shift toward sialylated glycans that may enhance immune evasion or adhesion while the overall program remains pro-tumorigenic.  
Evidence strength: direct cohort statistics for FUT4/KRT6A plus pathway annotation. Limitations: small gene overlap; no causal mechanistic data.

**Key genes and interaction modules**  
- DKK1 (risk, HR 1.475): canonical Wnt inhibitor; regulatory interaction within Wnt module; pathway co-membership with TLE1.  
- KRT6A (risk, HR 1.39): epithelial-mesenchymal transition marker; co-expression with glycosylation genes FUT4/RHOF; indirect relationship via cytoskeletal/glycan remodeling.  
- RHOF (risk, HR 1.403): Rho-family GTPase; regulatory interaction with actin cytoskeleton organization; pathway co-membership in small-GTPase signaling.  
- FUT4 (risk, HR 1.403): fucosyltransferase; regulatory interaction with CMAHP in O-glycan biosynthesis; pathway co-membership.  
- LDLRAD3 (risk, HR 1.42): LDL-receptor family; indirect relationship via membrane signaling; STRING co-occurrence with APP/FAM9A.  
- RGS20 (risk, HR 1.352): RGS-family GTPase regulator; direct physical interaction with GNAZ/GNB5 (STRING); pathway co-membership in G-protein signaling.  
- PITX3 (risk, HR 1.429): transcription factor; regulatory interaction in neural crest-derived programs; pathway co-membership in Wnt targets.  
- CRNDE (protective, HR 0.716): lncRNA; regulatory interaction; pathway co-membership with LINC01312.  
- CMAHP (protective, HR 0.706): sialic-acid hydroxylase; regulatory interaction with FUT4; pathway co-membership in glycosylation.  
- TLE1 (risk, HR 1.484): Groucho-family co-repressor; regulatory interaction within Wnt; pathway co-membership.

**Validation priorities**  
1. Mechanistic hypothesis: Test DKK1/TLE1/Wnt module via CRISPR knockout or small-molecule Wnt inhibitors in LUAD organoids; current dataset provides only HR associations, external evidence is limited to single LUAD papers; next step: functional validation in patient-derived models; exploratory hypothesis.  
2. Biomarker: Validate FUT4/KRT6A/RHOF mRNA or protein levels by qPCR/IF in independent LUAD cohorts for OS stratification; current dataset supplies HR/P/FDR; external evidence is sparse; next step: RT-qPCR in formalin-fixed paraffin-embedded archives; supported hypothesis.  
3. Interaction/network hypothesis: Confirm STRING-reported RHOF–ACTN1 or RGS20–GNAZ interactions by co-IP in LUAD cell lines; current dataset only co-expression/pathway membership; external evidence from STRING/OmniPath; next step: proximity ligation assays; exploratory hypothesis.  
4. Confounding or composition check: Assess tumor purity and stromal RNA fraction via ESTIMATE or CIBERSORT in the original cohort; current dataset lacks purity metrics; external evidence from TCGA standard pipelines; next step: re-analyze with purity-adjusted models; supported hypothesis.  
5. Therapeutic target: Evaluate whether small-molecule inhibitors of FUT4 or Wnt components (e.g., LGK974) show synergy with standard LUAD chemotherapy; current dataset provides no drug-target records; external evidence is limited to preclinical data; next step: in vitro drug-screening assays; exploratory hypothesis.

**Evidence grounding**  
All major programs, key genes, and associations rest on direct HR/P/FDR values from the supplied survival table (primary evidence). Pathway annotations (Wnt, O-glycan biosynthesis) derive from QuickGO/KEGG records; protein interactions from STRING; disease associations from GTEx/HPA tissue expression. These external layers are contextual and do not constitute independent statistical replication; no external-cohort HR/P/FDR values are available. No conflicts between sources, but glycosylation and Wnt signals show only partial gene coverage.

**Limitations and alternative explanations**  
- Extreme HR magnitudes (many 5e+21) with P = 0/FDR = 0 may reflect small-sample effects or perfect separation rather than true biology.  
- Predominance of non-coding RNAs and pseudogenes reduces interpretability; many lack clear protein-coding function.  
- Potential tumor-purity or stromal-composition bias, as LUAD specimens vary widely in immune-cell infiltration.  
- Absence of independent-cohort statistics precludes claims of replication or generalizability.  
- Possible batch/platform effects or unmeasured confounders (age, stage, treatment) that could inflate associations.  

These factors can be investigated by re-running survival models with purity covariates or external validation in larger, annotated cohorts. The current conclusions should be regarded as exploratory.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=11, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: xAI / grok-4.6

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 53/100 selected items (records returned); cbioportal 51/100 selected items (records returned); chembl 16/100 selected items (records returned); civic 1/100 selected items (records returned); clinicaltrials 6/100 selected items (records returned); clinvar 30/100 selected items (records returned); ensembl 11/100 selected items (partially returned; some queries failed); europepmc 362 articles / initial full-cohort RAG 100 queries + 4 current-round queries; some queries failed; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 14/100 selected items (records returned); humanbase 56/100 selected items (partially returned; some queries failed); intact 18/100 selected items (records returned); mygene 59/100 selected items (records returned); omnipath 3/100 selected items (records returned); opentargets 55/100 selected items (records returned); pubmed 202 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 17/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 17/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 2/100 selected items (records returned); string 14/100 selected items (records returned); trrust 4/100 selected items (records returned)
